Fennec Pharmaceuticals is a small stage biotechnology company focused on the development of PEDMARK TM (a unique formulation of Sodium Thiosulfate) for the prevention of ototoxicity from cisplatin in pediatric patients.
PEDMARK is an investigational drug and has not yet been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority.
Publications & Presentations
Helping the Kids of Today Become the Adults of Tomorrow
Hearing loss is a devastating and life-long impact on quality of life for children that can cause grade setbacks and learning problems. Fennec advocates for a better quality of life.
Fennec News
- February 14th, 2020 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2019 FINANCIAL RESULTS
- February 11th, 2020 FENNEC PHARMACEUTICALS COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION (NDA) TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARK™ AND ALSO SUBMITS MARKETING AUTHORIZATION APPLICATION (MAA) TO EUROPEAN MEDICINES AGENCY
- November 12th, 2019 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS